← 返回前沿论文

WT1 树突状细胞疫苗放射免疫治疗使终末期肺腺癌肿瘤显著缩小

英文原题:Radioimmunotherapy With WT1 Dendritic Cell Vaccine for End-Stage Lung Adenocarcinoma Markedly Shrinks Tumors.

PubMed 2023/11/06(内容时间) Cureus

研究概要

在伴有转移的晚期肺腺癌中,当前的标准治疗原则上不包括手术和放疗等积极癌症治疗。

中文摘要

在伴有转移的晚期肺腺癌中,目前的标准治疗原则上不包括手术和放疗等积极抗癌治疗。因此,当化疗无法继续时,患者通常转为姑息治疗。我们的患者为60多岁的IV期肺腺癌,正在接受化疗,但因严重副作用不得不中止。由于标准治疗已不再适用,他接受了放射免疫治疗联合WT1树突状细胞疫苗治疗。结果,巨大的肺癌显著缩小,血液检查显示免疫谱改善。肺癌生长受到抑制,患者完全无症状。完成放射免疫治疗后,患者继续过着与健康人相似的生活。本病例提示,对于不适合标准治疗的患者,放射免疫治疗可作为积极治疗手段。

展开英文摘要原文

In advanced lung adenocarcinoma with metastases, the current standard of care does not in principle include aggressive cancer treatment with surgery and radiotherapy. Therefore, when chemotherapy cannot be continued, the patient is generally switched to palliative care. Our patient with stage IV lung adenocarcinoma in his 60s was receiving chemotherapy, which had to be discontinued due to severe side effects. As standard treatment was no longer indicated, he underwent radioimmunotherapy combined with WT1 dendritic cell vaccine therapy. As a result, the massive lung cancer shrank significantly and blood tests showed an improved immune profile. The growth of the lung cancer was suppressed, and the patient is completely symptom-free. After completing radioimmunotherapy, the patient continues to live a life similar to that of a healthy person. This case suggests that radioimmunotherapy can be useful as an active treatment in patients who are not eligible for standard treatment.

论文信息

作者
Nagai H、Karube R、Zhao F
第一作者单位
Human and Environmental Studies, Tokai University, Kanagawa, JPN.Japan
通讯作者单位
Oncology, Ginza Phoenix Clinic, Tokyo, JPN.United States
文献类型
病例报告
期刊
Cureus2023 Nov
原文标识
PubMed 38074069 · DOI 10.7759/cureus.48412